221 related articles for article (PubMed ID: 26055143)
1. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.
Dragoj M; Milosevic Z; Bankovic J; Dinic J; Pesic M; Tanic N; Stankovic T
Tumour Biol; 2015 Nov; 36(11):8773-80. PubMed ID: 26055143
[TBL] [Abstract][Full Text] [Related]
2. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.
Andjelkovic T; Bankovic J; Milosevic Z; Stojsic J; Milinkovic V; Pesic M; Ruzdijic S; Tanic N
Cancer Biomark; 2011-2012; 10(6):277-86. PubMed ID: 22820083
[TBL] [Abstract][Full Text] [Related]
3. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer.
Wang J; Chen H; Liao Y; Chen N; Liu T; Zhang H; Zhang H
Tumour Biol; 2015 Sep; 36(9):6965-72. PubMed ID: 25861022
[TBL] [Abstract][Full Text] [Related]
5. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.
Andjelkovic T; Bankovic J; Stojsic J; Milinkovic V; Podolski-Renic A; Ruzdijic S; Tanic N
Transl Res; 2011 Jan; 157(1):19-28. PubMed ID: 21146147
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of cyclin Dl expression in non-small cell lung cancer].
Dworakowska D
Pneumonol Alergol Pol; 2005; 73(3):297-300. PubMed ID: 16989170
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
Bhaumik S; Ahmad F; Das BR
Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
[TBL] [Abstract][Full Text] [Related]
8. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
9. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
10. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
11. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
12. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
17. The EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.
Baykara O; Dalay N; Bakir B; Bulut P; Kaynak K; Buyru N
Int J Med Sci; 2017; 14(7):675-679. PubMed ID: 28824300
[No Abstract] [Full Text] [Related]
18. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
19. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.
Lei L; Jiang ZM; Li CH; Lu HY
Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
[TBL] [Abstract][Full Text] [Related]
20. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
